PharmaTimes https://pharmatimes.com in-depth news, features and insights for the pharmaceutical and healthcare sectors Wed, 20 May 2026 11:56:15 +0000 en-US hourly 1 https://pharmatimes.com/wp-content/uploads/2023/11/PT-icon-150x150.png PharmaTimes https://pharmatimes.com 32 32 232894315 KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy https://pharmatimes.com/news/koala-trial-opens-to-enrol-patients-for-first-in-human-kmcar-t-cell-therapy/ Wed, 20 May 2026 11:55:35 +0000 https://pharmatimes.com/?p=104574 Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma

]]> 104574 Pepaxti study supports use in wider myeloma population https://pharmatimes.com/news/pepaxti-study-supports-use-in-wider-myeloma-population/ Wed, 20 May 2026 11:46:42 +0000 https://pharmatimes.com/?p=104572 Phase 2 bridge data show consistent outcomes in patients with impaired kidney function

]]> 104572 UCB reports positive outcomes for bimekizumab in psoriatic arthritis https://pharmatimes.com/news/ucb-reports-positive-outcomes-for-bimekizumab-in-psoriatic-arthritis/ Tue, 19 May 2026 11:48:33 +0000 https://pharmatimes.com/?p=104570 Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic

]]> 104570 AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension https://pharmatimes.com/news/astrazeneca-wins-us-approval-for-first-in-class-baxfendy-in-hypertension/ Tue, 19 May 2026 11:34:58 +0000 https://pharmatimes.com/?p=104568 Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial

]]> 104568 Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies https://pharmatimes.com/news/cellbxhealth-partners-with-adventhealth-on-ctc-based-monitoring-in-two-major-cancer-studies/ Mon, 18 May 2026 08:49:37 +0000 https://pharmatimes.com/?p=104565 Parsortix platform to support minimally invasive analysis across various cancer trials

]]> 104565 Microbiotica reports positive results for MB097 in advanced melanoma https://pharmatimes.com/news/microbiotica-reports-positive-results-for-mb097-in-advanced-melanoma/ Mon, 18 May 2026 08:42:36 +0000 https://pharmatimes.com/?p=104563 Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment

]]> 104563 Prof Dr Wolfram Brugger https://pharmatimes.com/appointments/prof-dr-wolfram-brugger/ Thu, 14 May 2026 09:13:37 +0000 https://pharmatimes.com/?p=104560 Asgard has appointed Prof Dr Wolfram Brugger as CMO

]]> 104560 Kylie’s greatest hits https://pharmatimes.com/thought_leadership/kylies-greatest-hits/ Thu, 14 May 2026 09:04:29 +0000 https://pharmatimes.com/?p=104557 Building trust with patient organisations in the misinformation era

]]> 104557 MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration https://pharmatimes.com/news/mhra-to-open-new-northern-ireland-hub-to-strengthen-uk-wide-life-sciences-collaboration/ Wed, 13 May 2026 10:19:36 +0000 https://pharmatimes.com/?p=104555 Belfast base will expand regulatory support, boost innovation and deepen engagement

]]> 104555 Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial https://pharmatimes.com/news/novo-nordisk-data-shows-oral-semaglutide-delivers-significant-weight-loss-in-phase-3-trial/ Wed, 13 May 2026 10:16:23 +0000 https://pharmatimes.com/?p=104552 Responders achieved weight loss and improvements in physical function

]]> 104552